No Data
Solasia Pharma KK: Business Status of Product Development Products, etc. (3rd quarter of the fiscal year ending 2024/12)
Solasia Pharma KK: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
Solasia Pharma 9-Mos Loss Y871.00M Vs Loss Y768.00M
Stocks that moved the previous day include part2 REVOLUTION, RSC, pluszero, etc.
Name of stock <code> 25-day closing price⇒Change from previous day *SHIFT＜3697＞ 13840 -825. Small and medium-sized growth stocks are dominant. * Kawasaki Kisen <9107> 2030 -90 Recently, shipping stocks have been bought due to good earnings from Maersk, etc. * IDOM <7599> 994 -28 Still wary of FSA's on-site inspections. * Rigaku Holdings <268A> 1130 Be aware of the large amount of absorption and start with a public price below the absorption amount. * Canon Inc.-spons adr <7751>
The TSE Growth Market 250 index fell for the fourth consecutive day, with continued bargain hunting for low-priced stocks by process of elimination.
TOPIX Growth Market Index 757.15 -12.52 / Volume 0.2 billion 73.83 million shares / Trading value 95.2 billion yen TOPIX Growth Market 250 Index 589.30 -10.05 / Volume 96.65 million shares / Trading value 59.9 billion yen Today's growth market saw both the TOPIX Growth Market Index and TOPIX Growth Market 250 Index fall for the 4th consecutive day. The number of advancing stocks was 92, declining stocks 466, unchanged was 28. The U.S. stock market on the 24th had mixed results. The Dow Jones Industrial Average fell by 140.59 dollars.
Active and newly listed stocks during the morning session.
*Nomi Bosai <6744> 2974 +173 reacts favorably to better-than-expected performance guidance revision. *Konica Minolta <4902> 593.3 +32.1 Macquarie Securities upgrades investment rating. *Nidec Corporation sponsored ADR <6594> 3127 +142.5 Is the development progressing based on a review following the previous day's briefing? *Watami <7522> 945 +21 rumored to acquire Subway's Japan operation, etc. *Shin-Etsu Polymer <7970> 1474 +21 In addition to the good financial results, there is also an expansion of return measures.
No Data
No Data